HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Doorn, C. A. Articles by Watson, D. A. Search for Related Content PubMed PubMed Citation Articles by van Doorn, C. A. Articles by Watson, D. A.

European Journal of Cardio-Thoracic Surgery, Vol 9, 253-258, Copyright © 1995 by European Association for Cardio-thoracic Surgery

ARTICLES

Mitral valve replacement with the Carpentier-Edwards standard bioprosthesis: performance into the second decade

CA van Doorn, KD Stoodley, NR Saunders, RU Nair, GA Davies and DA Watson
Department of Cardiothoracic Surgery, Killingbeck Hospital, Leeds, UK.

From March 1978, 196 Carpentier-Edwards standard bioprostheses (stCE) were implanted in 194 patients. There were 154 isolated mitral valve replacements (MVR) and 42 aortic plus mitral valve replacements (AVR/MVR) with a mean follow-up of 7.05 (range 0-15.2) years and 7.15 (range 0-13.8) years, respectively. Freedom from structural valve failure at 10 years was 70.8% +/- 4.9% (MVR) and 59.6% +/- 11.1% (AVR/MVR). The incidence of structural valve failure increased sharply after 7 years. Freedom from thromboembolism was 83.0% +/- 3.8% (MVR) and 89.0 +/- 6.0% (AVR/MVR). Thromboembolic events were related to the presence of atrial fibrillation in patients not receiving anticoagulation. Anticoagulant-related haemorrhage was rare. Freedom from mitral valve prosthetic endocarditis at 10 years was 90.9% +/- 3.1% (MVR) and 86.1% +/- 8.4% (AVR/MVR). Prosthetic valve endocarditis was associated with more than 60% mortality. The probability of event- free survival at 10 years follow-up was 43.6% +/- 4.6% (MVR) and 33.3% +/- 8.6% (AVR/MVR). The performance of the stCE in the mitral position shows a low rate of thromboembolic events and anticoagulant-related haemorrhage, but the long-term performance of the prosthesis is unsatisfactory due to a high rate of structural valve failure. This confirms earlier reports.

This article has been cited by other articles:

				T. Gudbjartsson, T. Absi, and S. Aranki Mitral Valve Replacement Card. Surg. Adult, January 1, 2008; 3(2008): 1031 - 1068. [Full Text]

				H. V. Schaff and R. M. Suri Multiple Valve Disease Card. Surg. Adult, January 1, 2008; 3(2008): 1129 - 1158. [Full Text]

				H.-Y. Yu, Y.-L. Ho, S.-H. Chu, Y.-S. Chen, S.-S. Wang, and F.-Y. Lin Long-term evaluation of Carpentier-Edwards porcine bioprosthesis for rheumatic heart disease J. Thorac. Cardiovasc. Surg., July 1, 2003; 126(1): 80 - 89. [Abstract] [Full Text] [PDF]

				T. Gudbjartsson, S. Aranki, and L. H. Cohn Mechanical/Bioprosthetic Mitral Valve Replacement Card. Surg. Adult, January 1, 2003; 2(2003): 951 - 986. [Full Text]

				H. V. Schaff and D. H. Marsh Multiple Valve Disease Card. Surg. Adult, January 1, 2003; 2(2003): 1017 - 1045. [Full Text]